SCHEMBL25835371

SCHEMBL25835371

COc1nccc2nc(N)[nH]c12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 3/20 0.37
TYMS P04818 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KMT2A Q03164 2/20 0.35
MASP2 O00187 1/20 0.35
MEN1 O00255 1/20 0.35
AOC3 Q16853 1/20 0.35
AURKA O14965 1/20 0.35
TTK P33981 1/20 0.35
AURKB Q96GD4 1/20 0.35
INCENP Q9NQS7 1/20 0.35
PNP P00491 1/20 0.35
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
KDM4E B2RXH2 1/20 0.34
DHFR P00374 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
RAD52 P43351 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30622648 1.00 NUDT1 (0.37) NUDT1TYMSALDH1A1KMT2AMASP2
SCHEMBL12778715 0.79 BTK (0.33) MAPTBTKACSS2
SCHEMBL14690117 0.73 NUDT1 (0.43) NUDT1TYMSALDH1A1KMT2AMASP2
SCHEMBL30622661 0.72 APLNR (0.47)
SCHEMBL9693902 0.72 KDM4E (0.48) ALDH1A1KMT2AMEN1AURKAKDM4E
SCHEMBL29016874 0.72 CLK1 (0.36) ALDH1A1KMT2AMEN1NOS3NOS1
SCHEMBL24834182 0.70 DCPS (0.47) NUDT1ALDH1A1KMT2AMASP2MEN1
SCHEMBL31723877 0.70 DCPS (0.47) NUDT1ALDH1A1KMT2AMASP2MEN1
SCHEMBL9451594 0.70 BTK (0.40) NUDT1ALDH1A1KMT2AAURKATTK
SCHEMBL2447200 0.68 PDPK1 (0.49) ALDH1A1KDM4EMAPTRAD52BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346588-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS KUDA THERAPEUTICS INC (US) 2025-11-13 US disclosed
WO-2023234970-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS KUDA Therapeutics, Inc. (US) 2023-12-07 WO disclosed
WO-2023137356-A1 15-PGDH INHIBITORS VENTYX BIOSCIENCES, INC. (US) 2023-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346588-A1 IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS HIF1AN, HIF1A, EGLN2 NUDT1 1464/4885TYMS 2272/4885ALDH1A1 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.